Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other financing activities: 2017-2024

Historic Other financing activities for BridgeBio Pharma (BBIO) over the last 7 years, with Dec 2024 value amounting to $16.0 million.

  • BridgeBio Pharma's Other financing activities rose 34.42% to -$10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 476.91%. This contributed to the annual value of $16.0 million for FY2024, which is N/A change from last year.
  • BridgeBio Pharma's Other financing activities amounted to $16.0 million in FY2024, which was up 1,809.92% from $837,000 recorded in FY2022.
  • In the past 5 years, BridgeBio Pharma's Other financing activities registered a high of $24.1 million during FY2020, and its lowest value of $837,000 during FY2022.
  • Moreover, its 2-year median value for Other financing activities was $8.4 million (2022), whereas its average is $8.4 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Other financing activities rose by 0.70% in 2020, and later crashed by 94.79% in 2022.
  • Yearly analysis of 4 years shows BridgeBio Pharma's Other financing activities stood at $24.1 million in 2020, then slumped by 33.33% to $16.1 million in 2021, then slumped by 94.79% to $837,000 in 2022, then reached $16.0 million in 2024.